We are live on ! Find out more
BCM

Boxer Capital Management Portfolio holdings

AUM $1.33B Turnover 22.73%
1-Year Est. Return 864.5%
This Fund
S&P 500
This Quarter Est. Return
+54.02%
1 Year Est. Return
+864.5%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$762M
AUM Growth
+$305M
Cap. Flow
+$141M
Cap. Flow %
18.47%
Top 10 Hldgs %
63.32%
Holding
56
New
11
Increased
13
Reduced
3
Closed
2
Avg Time Held
0.5 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.5 years

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$17.6M
2
CRVS icon
Corvus Pharmaceuticals
CRVS
+$17.6M
3
RVMD icon
Revolution Medicines
RVMD
+$10.1M
4
VIR icon
Vir Biotechnology
VIR
+$9.89M
5
CORT icon
Corcept Therapeutics
CORT
+$9.35M

Top Sells

Rank Stock Value
1
CDTX icon
Cidara Therapeutics
CDTX
+$11.7M
2
PEPG icon
PepGen
PEPG
+$568K
3
HELP
Helus Pharma Inc. Common Stock
HELP
+$485K
4
NUVB.WS icon
Nuvation Bio Inc Warrants
NUVB.WS
+$88K
5
INO icon
Inovio Pharmaceuticals
INO
+$82.3K

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
2 Consumer Staples 0.31%
3 Miscellaneous 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TNGX icon
1
Tango Therapeutics
TNGX
$3.81B
$228M 29.87%
10,876,219
– –
2024 Q4
5 quarters
KOD icon
2
Kodiak Sciences
KOD
$5.52B
$51.9M 6.81%
1,361,000
+225,000
+20% +$5.81M
2024 Q4
5 quarters
RVMD icon
3
Revolution Medicines
RVMD
$40.9B
$48.6M 6.38%
500,000
+100,000
+25% +$10.1M
2024 Q4
5 quarters
KYMR icon
4
Kymera Therapeutics
KYMR
$9.01B
$27.4M 3.6%
329,100
– –
2024 Q4
5 quarters
CELC icon
5
Celcuity
CELC
$3B
$25.7M 3.37%
225,000
– –
2025 Q3
2 quarters
SRZN icon
6
Surrozen
SRZN
$293M
$22.3M 2.93%
766,318
+350,168
+84% +$8.39M
2025 Q4
1 quarter
ABVX icon
7
Abivax
ABVX
$8.04B
$22.3M 2.92%
200,000
+75,000
+60% +$8.88M
2025 Q3
2 quarters
TERN icon
8
DELISTED
Terns Pharmaceuticals
TERN
$19.8M 2.6%
375,000
– –
2025 Q4
1 quarter
PCVX icon
9
Vaxcyte
PCVX
$10.3B
$18.9M 2.48%
+325,000
New +$17.6M
2026 Q1
0 quarters
CAPR icon
10
Capricor Therapeutics
CAPR
$426M
$17.9M 2.35%
590,000
+265,000
+82% +$7.06M
2025 Q4
1 quarter
PTGX icon
11
Protagonist Therapeutics
PTGX
$8.92B
$17.9M 2.35%
170,000
– –
2025 Q2
3 quarters
VIR icon
12
Vir Biotechnology
VIR
$1.79B
$16.7M 2.2%
1,866,000
+1,241,000
+199% +$9.89M
2025 Q4
1 quarter
CRVS icon
13
Corvus Pharmaceuticals
CRVS
$834M
$16.1M 2.11%
+1,100,000
New +$17.6M
2026 Q1
0 quarters
PRAX icon
14
Praxis Precision Medicines
PRAX
$6.96B
$15M 1.97%
46,457
– –
2025 Q4
1 quarter
PTCT icon
15
PTC Therapeutics
PTCT
$5.1B
$13.6M 1.79%
200,000
– –
2025 Q3
2 quarters
PGEN icon
16
Precigen
PGEN
$2.63B
$13.5M 1.78%
3,500,000
+2,125,000
+155% +$8.72M
2025 Q3
2 quarters
DFTX icon
17
Definium Therapeutics
DFTX
$4.6B
$11.3M 1.49%
598,500
– –
2025 Q3
2 quarters
AMLX icon
18
Amylyx Pharmaceuticals
AMLX
$3.49B
$11.1M 1.46%
800,000
– –
2024 Q4
5 quarters
QURE icon
19
uniQure
QURE
$1.56B
$10.8M 1.42%
662,000
+372,000
+128% +$7.53M
2024 Q4
5 quarters
IRD icon
20
Opus Genetics
IRD
$334M
$10.2M 1.34%
+2,250,000
New +$7.78M
2026 Q1
0 quarters
CORT icon
21
Corcept Therapeutics
CORT
$12.4B
$10.1M 1.32%
+250,000
New +$9.35M
2026 Q1
0 quarters
URGN icon
22
UroGen Pharma
URGN
$1.79B
$8.99M 1.18%
500,000
– –
2025 Q2
3 quarters
REPL icon
23
Replimune Group
REPL
$1.11B
$8.99M 1.18%
1,175,000
+425,000
+57% +$3.25M
2024 Q4
5 quarters
COGT icon
24
Cogent Biosciences
COGT
$5.13B
$8.66M 1.14%
225,000
– –
2025 Q4
1 quarter
PALI icon
25
Palisade Bio
PALI
$268M
$8.4M 1.1%
4,799,875
– –
2025 Q4
1 quarter
1
2 3

Similar funds

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.33B AUM 29.71% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.33B AUM 27.72% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.33B AUM 37.42% 1-Year Est. Return
MIC
Means Investment Company Bangor, Maine $1.32B AUM 24.33% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.32B AUM 30.92% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $1.33B AUM 5.69% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $1.33B AUM 1,044.61% 1-Year Est. Return

Boxer Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Boxer Capital Management held 56 positions worth $762M, up 67% from $457M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Boxer Capital Management deployed $141M of net new capital in Q1 2026, opening 11 new positions and adding to 13 existing holdings. Its largest new stake was Vaxcyte: 325,000 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Consumer Staples and Miscellaneous.

On the sell side, the largest reduction was PepGen, an estimated $568K trimmed.

  • Boxer Capital Management's largest Q1 2026 buy was Vaxcyte: 325,000 shares worth $18.9M.
  • Boxer Capital Management added most to Revolution Medicines in Q1 2026, an estimated $10.1M increase.
  • Boxer Capital Management's biggest Q1 2026 reduction was PepGen, cutting an estimated $568K.
  • Boxer Capital Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $11.7M.
  • Boxer Capital Management's ten largest holdings make up 63% of its $762M portfolio in Q1 2026.
  • Boxer Capital Management opened 11 new positions and closed 2 in Q1 2026.
  • Boxer Capital Management's portfolio value rose 67% quarter-over-quarter to $762M.

Based on Boxer Capital Management's 13F filing for Q1 2026, filed 15 May 2026.